New evidence for HCPs: The evidence base for oral treatment in type 2 diabetes continues to grow. A new indirect treatment comparison, presented today at the #EASD2026 annual meeting, evaluated the highest dose of our oral GLP-1 alongside a higher dose of another oral medicine for type 2 diabetes. Generating this kind of evidence is part of how we support clinicians as they make treatment decisions. Read more at the link in our bio.